Apoteek't Groen Kruis SA
Apoteek't Groen Kruis reported total assets of 220,163 € at the end of the 2025 financial year (annual accounts filed with the NBB on 28 Jul 2026).
The score of Apoteek't Groen Kruis shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +105 % Total assets -22 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Apoteek't Groen Kruis's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 28 Jul 2026
- Year ended 31 Dec 2024filed on 30 Jul 2025
- Year ended 31 Dec 2023filed on 08 Aug 2024
- Year ended 31 Dec 2022filed on 25 Jul 2023
- Year ended 31 Dec 2021filed on 27 Jul 2022
Apoteek't Groen Kruis's financial analysis
- Solvency88.9%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Apoteek't Groen Kruis
Apoteek't Groen Kruis's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0403.720.730
- VAT number
- BE0403720730
- Peppol
- Registered · 0208:0403720730 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 01 Jan 1967
- Registered office
- 2900 Schoten
- Latest accounts
- 2025 · filed on 28 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Apoteek't Groen Kruis (SA) has been based in Schoten since 1967, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 38,339 € and equity of 195,790 €; its revenue is not published. Its solvency stands at 88.9%, above the median of its sector (44.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Apoteek't Groen Kruis
Companies in the same business, of comparable size and area, outside its group.
- Zwitserse Apotheek Retail sale of pharmaceutical products Wijnegem · balance sheet 498,014 €
- La Pharmacie du Parc Retail sale of pharmaceutical products Grez-Doiceau · balance sheet 210,632 €
- Apotheek Bisschoppenhof Retail sale of pharmaceutical products Antwerp · balance sheet 200,383 €
- Koltfarma Retail sale of pharmaceutical products Charleroi · balance sheet 488,225 €
- ThePharm Retail sale of pharmaceutical products Antwerp · balance sheet 593,897 €
- Lynapharma Retail sale of pharmaceutical products Saint-Gilles · balance sheet 177,178 €
- Ludaphar Retail sale of pharmaceutical products Beauvechain · balance sheet €1.80m
- ELA Services Retail sale of pharmaceutical products Uccle · balance sheet 920,384 €
Frequently asked questions about Apoteek't Groen Kruis
What is the revenue of Apoteek't Groen Kruis?
Apoteek't Groen Kruis files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Apoteek't Groen Kruis?
In Belgium, the VAT number is the company number prefixed with BE: BE0403720730 for Apoteek't Groen Kruis, if the company is VAT-registered. Its company number (CBE) is 0403.720.730.
Where is the registered office of Apoteek't Groen Kruis?
According to the CBE register, the registered office of Apoteek't Groen Kruis is in 2900 Schoten.
What is the equity of Apoteek't Groen Kruis?
At the close of the 2025 financial year, the equity of Apoteek't Groen Kruis amounts to 195,790 €, a solvency of 88.9% of total assets.
Who manages Apoteek't Groen Kruis?
The register lists 2 active mandates at Apoteek't Groen Kruis. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Apoteek't Groen Kruis
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →